Pembrolizumab May Shrink or Eliminate Tumors in Nearly 90% of Patients With Advanced Desmoplastic Melanoma
Pembrolizumab (Keytruda, Merck) can effectively shrink or eliminate tumors in patients with unresectable advanced desmoplastic melanoma, according to a new study in Nature Medicine.